Session » Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment
-
Abstract Number: 2552
Fatigue in Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Early Improvement Is Associated with Week 24 Outcomes in Acr 20, 50, and Health-Related Quality of Life
-
Abstract Number: 2553
Secukinumab Provides Early and Sustained Improvements in Health-Related Quality of Life in Patients with Psoriatic Arthritis: Pooled Results from the Secukinumab Phase 3 Trial Program
-
Abstract Number: 2554
Abatacept without Methotrexate in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of a Phase III, Randomized Study
-
Abstract Number: 2557
Efficacy of Ustekinumab on Spondylitis-Associated Endpoints in TNF-Naïve Active Psoriatic Arthritis Patients with Physician-Reported Spondylitis
-
Abstract Number: 2558
Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542)
-
Abstract Number: 2559
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study
-
Abstract Number: 2560
Efficacy of Guselkumab in Psoriasis Patients with Self-Reported Psoriatic Arthritis with Involvement of the Scalp, Nails, Hands, and Feet: A Pooled Analysis from 2 Pivotal Phase 3 Psoriasis Studies
-
Abstract Number: 2561
Rapid and Sustained Improvements in Patient-Reported Signs and Symptoms with Ixekizumab in Biologic-Naive and TNF-Inadequate Responder Patients with Psoriatic Arthritis
-
Abstract Number: 2562
Secukinumab Improves Grappa-Omeract Core Domains of Psoriatic Arthritis
-
Abstract Number: 2564
Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients
-
Abstract Number: 2566
Impact of Guselkumab Versus Placebo and Adalimumab on Patient Reported Outcomes in Patients with and without Psoriatic Arthritis in a Phase 3 Pivotal Psoriasis Study
-
Abstract Number: 2567
Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-Naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results through Week 24 from a Phase 3 Study
-
Abstract Number: 2568
Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial
-
Abstract Number: 2569
Association of Enthesitis with Achievement of Normal Quality of Life and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Adalimumab
-
Abstract Number: 2570
Probability of Achieving Low Disease Activity or Remission in Subjects with Active Psa Treated with Apremilast
-
Abstract Number: 2571
Adalimumab Serum Concentration Fails to Predict Achievement of Sustained Remission or Absence of Flare for Patients with Non-Radiographic Axial Spondyloarthritis
-
Abstract Number: 2572
Predictors for Use of Secukinumab 300mg over 150mg in Psoriatic Arthritis: A Meta-Analysis of Four Phase 3 Trials By Machine Learning
-
Abstract Number: 2573
The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Targeting Disease Remission in Axial Spondyloarthritis: A Systematic Literature Review
-
Abstract Number: 2574
Tapering TNF Inhibitors in Axial Spondyloarthritis: Systematicanalysisoftheliteratureandmeta-Analysis
-
Abstract Number: 2575
Long-Term Effects of TNF-Alpha Inhibitors on Bone Mineral Density and the Incidence of Vertebral Fractures in Patients with Ankylosing Spondylitis
-
Abstract Number: 2576
Anti-Drug Antibodies, Efficacy, and Impact of Concomitant Methotrexate in Ixekizumab-Treated Patients with Psoriatic Arthritis
-
Abstract Number: 2577
Long-Term Effect of Ixekizumab on Patient-Reported Outcomes in Patients with Psa and Inadequate Response to TNF Inhibitors: 2-Year Follow-up from a Phase 3 Study
-
Abstract Number: 2578
Exposure Response Analyses to Describe the Relationship between Ixekizumab Concentrations and Acr Responses in Psoriatic Arthritis Patients
-
Abstract Number: 2579
Ixekizumab Treatment Significantly Improves Enthesitis and Dactylitis in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials
-
Abstract Number: 2580
Predicting Treatment Persistence and Non-Persistence of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients: A Gender Comparison
-
Abstract Number: 2581
Comparing Treatment Patterns of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
-
Abstract Number: 2582
Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 Patient-Treatment Years Exposure
-
Abstract Number: 2583
Secukinumab Provides Early and Sustained Improvements in Health-Related Quality of Life in Patients with Ankylosing Spondylitis: A Pooled Analysis from the Secukinumab Phase 3 Trial Program
-
Abstract Number: 2584
Low Incidence of Both New-Onset and Flares of Uveitis in Secukinumab-Treated Patients with Ankylosing Spondylitis: Clinical Trial and Post-Marketing Safety Analysis
-
Abstract Number: 2585
Secukinumab Immunogenicity in Patients with Psoriatic Arthritis and Ankylosing Spondylitis during a 52-Week Treatment Period
-
Abstract Number: 2586
Changes in Lymphocytes and Lymphocyte Subsets in Tofacitinib-Treated Patients with Psoriatic Arthritis
-
Abstract Number: 2587
The Impact of Tumor Necrosis Factor Inhibitors on Diabetes Mellitus Among Patients with Inflammatory Arthritis
-
Abstract Number: 2588
Baseline Pain Severity As a Predictor of Pain Improvement Following Treatment with Tofacitinib in Psoriatic Arthritis
-
Abstract Number: 2590
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
-
Abstract Number: 2591
Real-World Use of Secukinumab in Axial Spondyloarthritis: First Year Data from the Czech National Registry
-
Abstract Number: 2592
Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry
-
Abstract Number: 2593
Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis : Results from a Randomized, Double-Blind, Phase III Study
-
Abstract Number: 2594
Median Time to Pain Improvement in Patients with Psoriatic Arthritis Treated with Tofacitinib
-
Abstract Number: 2595
Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany
-
Abstract Number: 2596
Real-World Long-Term Effectiveness of Switching between Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register
-
Abstract Number: 2597
The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Patient Reported Outcomes in Axial Spondyloarthritis; A Systematic Literature Review and a Call for Action
-
Abstract Number: 2601
Nonsteroidal Anti-Inflammatory Drugs Attenuate Active Inflammatory Sacroiliac Joint Lesions in Patients with Early Axial Spondyloarthritis
-
Abstract Number: 2602
Evolution of Patient Characteristics in the Era of Biological Treatment of Psoriatic Arthritis: 18-Year Belgian Experience from Leuven Spondyloarthritis Biologics Cohort (BioSPAR)
-
Abstract Number: 2603
Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders
-
Abstract Number: 2605
Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration
-
Abstract Number: 2606
Long-Term Inhibition of Radiographic Progression with Originator Adalimumab in Patients with Moderate to Severe Psoriatic Arthritis with or without Radiographic Damage at Baseline
-
Abstract Number: 2607
Early Achievement of ASDAS-Major Improvement in Patients with Ankylosing Spondylitis Treated with TNF-α Blockers Is Associated with a Prominent Longterm Improvement in Metrologic Indices
-
Abstract Number: 2608
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study
-
Abstract Number: 2609
Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice
-
Abstract Number: 2610
Certolizumab Pegol Serum Levels ≥20 Mg/L Are Associated with Treatment Response in Patients with Axial Spondyloarthritis
-
Abstract Number: 2611
Multidrug Resistant AxSpA: No Advantage of Switching Class in Patients with Inadequate Response to Two Prior TNFi Agents
-
Abstract Number: 2612
Utility of Infiltration with Steroids in Dactilitis. Is the Infiltration Guided By Ecography Better THAN Conventional?
-
Abstract Number: 2613
Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
-
Abstract Number: 2614
The Effect of Secukinumab on the Immunogenicity of Influenza Vaccine in Patients with Psoriatic Arthritis
-
Abstract Number: 2615
The Effect of Smoking on Response to Tumour Necrosis Factor-Alpha Inhibitor Treatment in Psoriatic Arthritis Patients: Results from the Turkbio Registry
-
Abstract Number: 2616
The Effect of Smoking on Response to Tumor Necrosis Factor-Alpha Inhibitor Treatment in Ankylosing Spondylitis Patients: Results from the Turkbio Registry
-
Abstract Number: 2617
Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
-
Abstract Number: 2618
Drug Survival of Non TNF Inhibitors Bdmards in Psoriatic Arthritis (Ustekinumab/Secukinumab) : A Real-Word Multicentric Cohort of 161 Patients
-
Abstract Number: 2619
Effect of Statins on CRP Elevation in Patients with Psoriatic Arthritis
-
Abstract Number: 2620
The Treatment Choices and Response for a Psoriatic Arthritis Inception Cohort
-
Abstract Number: 2621
Predictors of Survival of Adalimumab Treatment in the Management of Ankylosing Spondylitis and Psoriatic Arthritis in Canadian Routine Care
-
Abstract Number: 2622
Regional and Temporal Variation in the Baseline Profile of Ankylosing Spondylitis Patients Initiating Adalimumab Following Failure of Non-Biologic Treatment in Canadian Routine Care
-
Abstract Number: 2623
Efficacy of TNF Inhibitors and Predictive Factors of Clinical Presentation in Patients with Psoriatic Arthritis
-
Abstract Number: 2624
Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis